Secondary Directs: Tonic for the Biotech Venture Financing Model?
This article was originally published in Start Up
Executive Summary
With the biotech VC model battered by miserable public markets on the one hand and too-few M&A exits on the other, some firms with adequate resources are looking to lower their total investment cost by buying, at big discounts, portfolio assets from other investors. But secondary investing is a very different game. Because the model and returns are so different, most VCs still say they're likely to avoid secondary direct investing - but given the longer-term problems of the VC model, some may begin to adopt it as a short-term tactic.
You may also be interested in...
Secondary Investor Saints Capital Offers VCs A Third Way Out
Secondary firms such as Saints, which is raising a $300 million seventh fund, step in to acquire stakes from other VCs at the end of their funds’ lifespans. With a biotech VC shakeout in progress, the secondaries are banking on more opportunities soon.
Highlights from PSA: Will Investors Rise Over Reimbursement Hurdles?
At our September 2009 Pharmaceutical Strategic Alliances meeting, a recurring theme concerned the growing importance of factoring reimbursement hurdles into drug development decisions. Where does that start? In some cases, at Series A.
Highlights from PSA: Will Investors Rise Over Reimbursement Hurdles?
At our September 2009 Pharmaceutical Strategic Alliances meeting, a recurring theme concerned the growing importance of factoring reimbursement hurdles into drug development decisions. Where does that start? In some cases, at Series A.